Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Short-term Investments (2016 - 2025)

Vanda Pharmaceuticals' Short-term Investments history spans 16 years, with the latest figure at $179.0 million for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 34.27% to $179.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $179.0 million, a 34.27% decrease, with the full-year FY2025 number at $179.0 million, down 34.27% from a year prior.
  • Short-term Investments hit $179.0 million in Q4 2025 for Vanda Pharmaceuticals, down from $223.7 million in the prior quarter.
  • Over the last five years, Short-term Investments for VNDA hit a ceiling of $405.4 million in Q3 2022 and a floor of $147.3 million in Q1 2023.
  • Historically, Short-term Investments has averaged $294.7 million across 5 years, with a median of $295.4 million in 2021.
  • Biggest five-year swings in Short-term Investments: crashed 59.99% in 2023 and later soared 82.58% in 2024.
  • Tracing VNDA's Short-term Investments over 5 years: stood at $380.7 million in 2021, then decreased by 12.85% to $331.8 million in 2022, then decreased by 23.92% to $252.4 million in 2023, then rose by 7.88% to $272.3 million in 2024, then tumbled by 34.27% to $179.0 million in 2025.
  • Business Quant data shows Short-term Investments for VNDA at $179.0 million in Q4 2025, $223.7 million in Q3 2025, and $244.6 million in Q2 2025.